Thus, the combination of baseline ANG2 and VEGF levels might be a useful biomarker to predict the deterioration of the liver functional reserve in patients with unresectable HCC who are treated with lenvatinib. This evidence concerns the gene ANGPT2 and hepatocellular carcinoma.